Spectral AI shares surge 17.08% after-hours on $31.7M BARDA funding for FDA approval push.

Spectral AI Inc. surged 17.08% in after-hours trading following the announcement of a $31.7M non-dilutive BARDA funding award to advance its DeepView AI imaging system toward FDA approval. The funding, part of a $150M potential contract, validates the company’s long-term strategy and provides critical capital to navigate regulatory hurdles, with FDA clearance expected to unlock further funding and commercialization. The move reflects investor optimism about the technology’s potential in medical diagnostics and the immediate financial relief for a company with negative equity and substantial operational losses.